Literature DB >> 8663222

Kinetics of blood coagulation factor Xaalpha autoproteolytic conversion to factor Xabeta. Effect on inhibition by antithrombin, prothrombinase assembly, and enzyme activity.

E L Pryzdial1, G E Kessler.   

Abstract

Autoproteolysis of blood coagulation factor Xa (FXa) results in the excision of a 4-kDa fragment (beta-peptide) from the intact subform, factor Xaalpha (FXaalpha), to yield factor Xabeta (FXabeta). In the preceding paper, we showed that generation of FXabeta leads to expression of a plasminogen binding site. FXabeta may consequently participate in fibrinolysis; therefore, the timing of subform conversion compared with thrombin production is important. In the current study we evaluated the kinetics of FXabeta generation, which showed that autoproteolysis of FXaalpha followed a second order mechanism where FXaalpha and FXabeta behaved as identical enzymes. Rate constants of 9 and 172 M-1 s-1 were derived, respectively, in the absence and presence of FXaalpha binding to procoagulant phospholipid. Under identical conditions the latter is estimated to be 6 orders of magnitude slower than thrombin generation by prothrombinase. Since heparin binding and prothrombin recognition have been previously attributed to a region of FXaalpha proximal to the beta-peptide, functional comparisons were conducted using homogeneous and stabilized preparations of FXaalpha and FXabeta. Comparisons included 1) the recognition of small substrates; 2) the rate of interaction with antithrombin/heparin; 3) the assembly of prothrombinase; and 4) the activation of prothrombin by prothrombinase. Although the beta-peptide neighbors a probable functional region in FXaalpha, conversion to FXabeta was not observed to influence these functions. The data support a model where FXaalpha is predominantly responsible for thrombin generation and where slow conversion to FXabeta coordinates coagulation and the initiation of fibrinolysis at sites of prothrombinase assembly.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8663222     DOI: 10.1074/jbc.271.28.16621

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Thrombolysis by chemically modified coagulation factor Xa.

Authors:  E L G Pryzdial; S C Meixner; K Talbot; L J Eltringham-Smith; J R Baylis; F M H Lee; C J Kastrup; W P Sheffield
Journal:  J Thromb Haemost       Date:  2016-08-17       Impact factor: 5.824

2.  Plasmin-mediated proteolysis of human factor IXa in the presence of calcium/phospholipid: Conversion of procoagulant factor IXa to a fibrinolytic enhancer.

Authors:  Amy E Schmidt; Kanagasabai Vadivel; Julian Whitelegge; Satya Paul Bajaj
Journal:  J Thromb Haemost       Date:  2020-03-30       Impact factor: 5.824

3.  Structure and dynamics of zymogen human blood coagulation factor X.

Authors:  Divi Venkateswarlu; Lalith Perera; Tom Darden; Lee G Pedersen
Journal:  Biophys J       Date:  2002-03       Impact factor: 4.033

4.  A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa.

Authors:  Genmin Lu; Francis R DeGuzman; Stanley J Hollenbach; Mark J Karbarz; Keith Abe; Gail Lee; Peng Luan; Athiwat Hutchaleelaha; Mayuko Inagaki; Pamela B Conley; David R Phillips; Uma Sinha
Journal:  Nat Med       Date:  2013-03-03       Impact factor: 53.440

5.  Ca2+-dependent and phospholipid-independent binding of annexin 2 and annexin 5.

Authors:  Nicole D Brooks; Jean E Grundy; Nadine Lavigne; Mélanie C Derry; Christina M Restall; C Roger MacKenzie; David M Waisman; Edward L G Pryzdial
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

6.  Factor Xa binding to annexin 2 mediates signal transduction via protease-activated receptor 1.

Authors:  Gourab Bhattacharjee; Jasimuddin Ahamed; Rafal Pawlinski; Cheng Liu; Nigel Mackman; Wolfram Ruf; Thomas S Edgington
Journal:  Circ Res       Date:  2008-01-03       Impact factor: 17.367

7.  Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors.

Authors:  Daniël Verhoef; Koen M Visscher; C Ruben Vosmeer; Ka Lei Cheung; Pieter H Reitsma; Daan P Geerke; Mettine H A Bos
Journal:  Nat Commun       Date:  2017-09-13       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.